1. Efficacy of claudin 18.2 positive patients targeted regimen compared to alternative regimens.
| Trial name | NCT Trial No. | Phase | Sample size | Therapy | OS | mPFS | ORR |
| OS, overall survival; mPFS, median progression-free survival; ORR, objective response rate; IL, interleukin; EOX, epirubicin, oxaliplatin and capecitabine. | |||||||
| Sahin-
2009 (6) |
NCT00909025 | I | 15 | Zolbetuximab
(single-dose escalation) |
− | − | − |
| MONO-
2013 (7) |
NCT01197885 | IIA | 43 | Zolbetuximab | − | 14.5 weeks | 9% |
| PILOT-
2014 (8) |
NCT01671774 | I | 32 | IMAB362 + zoledronic
acid + IL-2 |
40 weeks | 12.7 weeks | − |
| FAST-
2015 (9) |
NCT01630083 | IIB | 161 | zolbetuximab + EOX vs. randomized EOX | 13.2 months vs. 8.4 months | 7.5 months vs. 5.3 months | 39% vs. 25% |
| Zhan
2019 (10) |
NCT03159819 | I | 12 (7) | Claudin 18.2-specific chimeric antigen receptor T cells | − | 130 days | 42.8% |